If you are experiencing a medical emergency, please call 911 or seek care at an emergency room.
Bisphenol A (BPA) is a high-production-volume industrial chemical used in producing polycarbonate plastics and epoxy resins used in consumer products, such as storage containers for foods and beverages, medical devices, and thermal paper. The predominant human exposure is from food containers. Low levels of monomer can migrate from these products and there has been much controversy as to the potential toxicity of this BPA exposure.
FDA, under an Interagency Agreement between NCTR and the National Institute of Environmental Health Sciences, has conducted a series of studies in the past decade to address data gaps the FDA Science Board identified. Pharmacokinetic studies across several species have indicated that BPA undergoes rapid and extensive metabolic inactivation in the gut and liver, with the degree of inactivation in young animals varying across species.
Dr. Barry Delclos is a Research Pharmacologist at FDA’s National Center for Toxicological Research. His early research efforts focused on chemical carcinogenesis and later shifted to toxicities associated with endocrine active agents and modulation of toxicity by dietary factors. Dr. Delclos has served as Principal Investigator on a series of studies conducted under an Interagency Agreement between FDA and the National Institute of Environmental Health Sciences to evaluate aspects of the hypothesis that exposure to low levels of hormonally active agents, particularly during development, adversely affects human health, including reproductive function and carcinogenesis.
K. Barry Delclos, Ph.D.
Division of Biochemical Toxicology
FDA’s National Center for Toxicological Research
Thursday, September 13, 2018
12:00 pm to 1:00 pm
Learn more and register here.
The FDA Grand Rounds are webcast every other month to highlight cutting-edge research underway across the Agency and its impact on protecting and advancing public health. Each session features an FDA scientist presenting on a key public health challenge and how FDA is applying science to its regulatory activities. The 45-minute presentation is followed by questions from the audience.